{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470475028
| IUPAC_name = [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2''H''-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-propanoylpiperazine-1-carboxylate
| image = Suproclone.svg
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 77590-92-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 53696
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 48481
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J4AM5D708G
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05975

<!--Chemical data-->
| C=22 | H=22 | Cl=1 | N=5 | O=4 | S=2 
| molecular_weight = 520.024 g/mol
| smiles = O=C(N5CCN(C(=O)OC4C=1SCCSC=1C(=O)N4c2nc3nc(Cl)ccc3cc2)CC5)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H22ClN5O4S2/c1-2-16(29)26-7-9-27(10-8-26)22(31)32-21-18-17(33-11-12-34-18)20(30)28(21)15-6-4-13-3-5-14(23)24-19(13)25-15/h3-6,21H,2,7-12H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IBAUKGNDWVSETP-UHFFFAOYSA-N
}}

'''Suproclone''' is a [[sedative]] and [[anxiolytic]] drug in the [[cyclopyrrolone]] family of drugs, developed by the French pharmaceutical company Rh√¥ne-Poulenc.<ref>{{cite web |author=Psychotropics.dk |title=suproclone |url=http://www.psychotropics.dk/moleculeView/default.aspx?ID=1532&Catalogtype=A&ChapterID=9&Thissortorder=1  |accessdate=24 August 2009}}</ref> Other cyclopyrrolone drugs include [[zopiclone]], [[pagoclone]] and [[suriclone]]. 

Suproclone is very similar in structure to the related drug [[suriclone]], but little information has been published about it specifically. However it can be expected that the mechanism of action by which suproclone produces its sedative and anxiolytic effects is by modulating benzodiazepine receptors (resulting in an increased response to endogenous [[GABA]]), in a similar manner to other drugs of this class.<ref>Colin R. Gardner. Pharmacological profiles in vivo of benzodiazepine receptor ligands. Drug Development Research 1988. 12(1):1-28.</ref><ref>Ian L. Martin, Adam Doble, David J. Nutt. Calming the Brain: Benzodiazepines and Related Drugs from Laboratory to Clinic. Informa Healthcare (October 24, 2003). {{ISBN|1-84184-052-1}}</ref>

==References==
<references/>

{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Carbamates]]
[[Category:Chloroarenes]]
[[Category:Cyclopyrrolones]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Lactams]]
[[Category:Naphthyridines]]
[[Category:Sedatives]]
[[Category:Sulfur heterocycles]]
[[Category:Piperazines]]

{{sedative-stub}}